Prostate mucinous adenocarcinoma with signet ring cell

Gümüş, Eyüp; Yılmaz, Banu; Miroğlu, Cengiz

doi:10.1046/j.0919-8172.2003.00597.x

Cited by 19 publications

(21 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mucinous adenocarcinoma of the prostate is only rarely associated with true intracellular mucin positive ''signet ring cells'' unlike its counterparts in the bladder, urethra, or gastrointestinal tract. 1,13,14,17,29,34,36 Positive staining for PSA and prostate-specific acid phosphatase along with typically negative staining for CDX2 identifies the tumor as being of prostatic origin.…”

Section: Discussionmentioning

confidence: 97%

Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy

Osunkoya

Nielsen²,

Epstein³

2008

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Mucinous adenocarcinoma of the prostate is one of the least common variants of prostate cancer. The prognosis of this variant of prostate cancer remains controversial. We present 47 cases (1991 to 2006) of mucinous carcinomas treated by radical prostatectomy. Mean patient age at diagnosis was 56 years (range: 44 to 69 y). The mean preoperative prostate-specific antigen (PSA) level was 9.0 ng/mL (range: 1.9 to 34.3 ng/mL). Clinical stages were T1c (34 cases), T2a (7 cases), and T2b (6 cases). The mean percentage of tumor composed of the mucinous component was 52% (range: 25% to 90%). The mean Gleason score was 7 with scores of 6 in 6 cases (12.8%), 7 in 37 cases (78.7%), and 8 in 4 cases (8.5%). Margins were positive in 4 cases of mucinous adenocarcinoma of the prostate. Only 2 cases had isolated margin positivity in the nonmucinous acinar component of cancer. In 12 cases (25.5%), mucinous adenocarcinoma had established extraprostatic extension (EEPE). Eight cases (17.0%) had isolated EEPE of nonmucinous cancer. The 1 lymph node metastasis contained nonmucinous cancer. All together, taking into account both the mucinous and nonmucinous tumor, 20/47 cases (42.5%) had EEPE and 6/47 (12.7%) had positive margins. The 1 lymph node metastasis contained nonmucinous cancer. The mean follow-up for those without progression was 5.6 years (median 6 y, range: 1 to 15 y). One patient (2.1%) progressed 3 years after his radical prostatectomy (5 y actuarial progression-free risk 97.2%). Using the Kattan nomogram, the predicted mean 5-year PSA progression-free risk for nonmucinous prostate cancer with the same PSA and postoperative findings as in the current study was 85.4%. This study confirms that mucinous adenocarcinoma of the prostate treated by radical prostatectomy is not more aggressive, and possibly even less aggressive than nonmucinous prostatic adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 97%

Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy

Osunkoya

Nielsen²,

Epstein³

2008

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…Furthermore, the mucinous component may not be accurately representative of the tumor, and in these cases a biopsy diagnosis of prostatic adenocarcinoma with mucinous features should be rendered (Figs. 12,13,17,20,32 During carcinogenesis, typical acinar prostatic carcinoma may have focal mucinous differentiation in which the mucin is not confined to the lumina of neoplastic glands and it dissects through the prostatic stroma forming extracellular mucin pools containing individual glands or cribriforming nests of neoplastic cells. 18 A diagnosis of primary mucinous prostatic adenocarcinoma can only be considered in a prostatectomy specimen when the tumor has been thoroughly sampled.…”

Section: Pathologic Diagnosis Of Primary Mucinous Adenocarcinoma Of Tmentioning

confidence: 99%

“…18 A diagnosis of primary mucinous prostatic adenocarcinoma can only be considered in a prostatectomy specimen when the tumor has been thoroughly sampled. 2,4,[10][11][12][13][14]16,17,20,25,32,59,60 The criteria of Elbadawi et al, 2 expanded upon by Sousa Escando´n et al 60 and Osunkoya et al,11 are listed in Table 2. 16,46,59 Prostatic adenocarcinomas will secrete some degree of mucosubstance in approximately 60% to 90% of tumors, depending upon the processing technique utilized.…”

Section: Pathologic Diagnosis Of Primary Mucinous Adenocarcinoma Of Tmentioning

confidence: 99%

“…9,11,[34][35][36][37][38][39] In addition, a case of a metastasis to a postlaparoscopic radical prostatectomy trochar port-site has been reported. 14,30,32 Elevation of serum PSA was found in 77.8% of mucinous carcinoma cases by Saito and Iwaki 17 but no elevation was observed in most cases of signet ring cell prostatic adenocarcinoma or mucinous prostatic adenocarcinoma with signet ring cells. 9,11,41,42 The mean preoperative PSA level was 9.0 ng/mL (range, 1.9 to 34.3 ng/mL) in the study by Osunkoya et al 11 Cases with a low incidence of increased prostate tumor markers may be associated with the presence of signet ring cell differentiation.…”

mentioning

confidence: 95%

“…[25][26][27][28][29] In addition, a mucoid-appearing urethral discharge (mucosuria) may be observed with prostatic massage, and hydronephrosis has also been found in both primary mucinous prostatic carcinoma and signet ring cell prostatic carcinoma. 11,[31][32][33][34][35] Additional sites of metastatic mucinous prostatic adenocarcinoma that have been reported include: the brain, kidney, adrenal glands, liver, peritoneum, spleen and pancreas, skin, and bronchus, as well as the seminal vesicles, urethra, perineum, and scrotum involved by direct local extension. 4 The average patient age at the time of diagnosis of mucinous prostatic adenocarcinoma was found to be 56 years (range, 44 to 69 y) by Osunkoya et al, 11 66 years (range, 32 to 93 y) by Saito and Iwaki, 17 and 59 years (range, 45 to 70 y) by Lane et al 18 The metastatic pattern of conventional acinar and mucinous prostatic adenocarcinoma appears similar-for example, the bone is the most common site, once thought uncommon in mucinous prostatic adenocarcinoma, followed by lymph nodes and the lungs.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Mucin-producing Tumors and Tumor-like Lesions Involving the Prostate

Bohman

Osunkoya

2012

Advances in Anatomic Pathology

View full text Add to dashboard Cite

Mucin-producing tumors of the prostate include both primary and secondary tumors with mucinous differentiation or features involving the prostate gland. These tumors are relatively rare and have variable prognostic and therapeutic implications. Primary mucinous (colloid) adenocarcinoma of the prostate is defined as prostatic adenocarcinoma with mucinous differentiation involving 25% or more of the entire tumor. Another primary tumor of the prostate that may have mucinous features is primary mucin-producing urothelial-type adenocarcinoma of the prostate (mucinous prostatic urethral adenocarcinoma). Primary mucin-producing urothelial-type adenocarcinoma of the prostate is a distinct entity that typically arises from the prostatic urethra possibly from urethritis glandularis or glandular metaplasia with malignant transformation, and it is analogous to adenocarcinoma with mucinous differentiation arising from the urinary bladder. Signet ring cell tumors of the prostate, though rare, may also have mucinous features. Secondary tumors with mucinous differentiation that may involve the prostate include adenocarcinomas of the urinary bladder and colorectum. Pathologists should also be aware of mucin-producing tumor-like lesions involving the prostate, including mucinous metaplasia, and benign Cowper glands that may mimic malignancy. Herein we present an updated and comprehensive review of the clinicopathologic, immunohistochemical, molecular, and prognostic features of mucinous tumors and tumor-like lesions involving the prostate gland, with emphasis on mucinous prostatic adenocarcinoma and its mimickers, including potential diagnostic pitfalls.

show abstract

Left testicular and pulmonary metastases of mucinous adenocarcinoma of the prostate after robot‐assisted radical prostatectomy

et al. 2023

View full text Add to dashboard Cite

Introduction We present a case of mucinous adenocarcinoma of the prostate with testicular and lung metastases following robot‐assisted radical prostatectomy, androgen deprivation therapy, and radiotherapy. Case presentation A 73‐year‐old man with a prostate‐specific antigen level of 4.3 ng/mL was diagnosed with prostate cancer. Following the robot‐assisted radical prostatectomy, the pathological diagnosis was mucinous adenocarcinoma of the prostate (pT3bpN0, Gleason score of 4 + 4). Salvage hormonal therapy and irradiation were performed after the prostatectomy. Enlargement of the left testis was noted, and 28 months after prostatectomy, computed tomography detected a left testicular tumor and nodular lesions in the bilateral lungs. The histopathological diagnosis of left high orchiectomy was metastasis of a mucinous adenocarcinoma of the prostate. Chemotherapy with docetaxel followed by cabazitaxel was initiated. Conclusion Mucinous prostate adenocarcinoma with distal metastases following prostatectomy has been managed for longer than 3 years with multiple treatments.

show abstract

Prostate mucinous adenocarcinoma with signet ring cell

Cited by 19 publications

References 6 publications

Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy

Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy

Mucin-producing Tumors and Tumor-like Lesions Involving the Prostate

Left testicular and pulmonary metastases of mucinous adenocarcinoma of the prostate after robot‐assisted radical prostatectomy

Contact Info

Product

Resources

About